Erratum: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP (Cancer Cell (2013) 23(5) (618–633) (S153561081300127X) (10.1016/j.ccr.2013.03.013));Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

Cancer Cell

Volumn 23, Issue 5, 2013, Pages 618-633

  Lu, Min ^a   Breyssens, Hilde ^a   Salter, Victoria ^a   Zhong, Shan ^a   Hu, Ying ^a   Baer, Caroline ^a   Ratnayaka, Indrika ^a   Sullivan, Alex ^a   Brown, Nicholas R ^f   Endicott, Jane ^f   Knapp, Stefan ^b,e   Kessler, Benedikt M ^c,e   Middleton, Mark R ^f   Siebold, Christian ^d   Jones, E Yvonne ^d   Sviderskaya, Elena V ^g   Cebon, Jonathan ^h   John, Thomas ^h   Caballero, Otavia L ⁱ   Goding, Colin R ^a   Lu, Xin ^a   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b Structural Genomics Consortium   (United Kingdom)

^c Centre of Cellular and Molecular Physiology   (United Kingdom)

^d Division of Structural Biology   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; ETOPOSIDE; IASPP PROTEIN; MONOMER; NUTLIN 3; PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; VEMURAFENIB;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; MELANOMA METASTASIS; METASTATIC MELANOMA; MITOSIS INHIBITION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

EID: 84877826693     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.09.019     Document Type: Erratum

References (39)

1. Avery-Kiejda K.A., Bowden N.A., Croft A.J., Scurr L.L., Kairupan C.F., Ashton K.A., Talseth-Palmer B.A., Rizos H., Zhang X.D., Scott R.J., Hersey P. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 2011, 11:203.
2. Bell H.S., Ryan K.M. iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res. 2008, 68:4959-4962.
3. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., Hsieh J.K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 2003, 33:162-167.
4. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 2006, 38:1133-1141.
5. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 2006, 38:1133-1141.
6. Cheok C.F., Kua N., Kaldis P., Lane D.P. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 2010, 17:1486-1500.
7. Chikh A., Matin R.N., Senatore V., Hufbauer M., Lavery D., Raimondi C., Ostano P., Mello-Grand M., Ghimenti C., Bahta A., et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J. 2011, 30:4261-4273.
8. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Bröcker E.B., LeBoit P.E., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353:2135-2147.
9. de Lange J., Ly L.V., Lodder K., Verlaan-de Vries M., Teunisse A.F., Jager M.J., Jochemsen A.G. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 2012, 31:1105-1116.
10. Emanuel S., Rugg C.A., Gruninger R.H., Lin R., Fuentes-Pesquera A., Connolly P.J., Wetter S.K., Hollister B., Kruger W.W., Napier C., et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005, 65:9038-9046.
11. Fogal V., Hsieh J.K., Royer C., Zhong S., Lu X. Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. EMBO J. 2005, 24:2768-2782.
12. Fredersdorf S., Milne A.W., Hall P.A., Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am. J. Pathol. 1996, 148:825-835.
13. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., Haupt S., de Lange J., Yip D., et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 2012, 18:1239-1247.
14. Georgieva J., Sinha P., Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J. Clin. Pathol. 2001, 54:229-235.
15. Houben R., Hesbacher S., Schmid C.P., Kauczok C.S., Flohr U., Haferkamp S., Müller C.S., Schrama D., Wischhusen J., Becker J.C. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS ONE 2011, 6:e22096.
16. Ji Z., Njauw C.N., Taylor M., Neel V., Flaherty K.T., Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol. 2012, 132:356-364.
17. Jiang L., Siu M.K., Wong O.G., Tam K.F., Lu X., Lam E.W., Ngan H.Y., Le X.F., Wong E.S., Monteiro L.J., et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin. Cancer Res. 2011, 17:6924-6933.
18. Johnson L.N. Substrates of mitotic kinases. Sci. Signal. 2011, 4:pe31.
19. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
20. Muthusamy V., Hobbs C., Nogueira C., Cordon-Cardo C., McKee P.H., Chin L., Bosenberg M.W. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 45:447-454.
21. Notari M., Hu Y., Koch S., Lu M., Ratnayaka I., Zhong S., Baer C., Pagotto A., Goldin R., Salter V., et al. Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc. Natl. Acad. Sci. USA 2011, 108:16645-16650.
22. Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal. 2010, 3:ra3.
23. Polsky D., Bastian B.C., Hazan C., Melzer K., Pack J., Houghton A., Busam K., Cordon-Cardo C., Osman I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001, 61:7642-7646.
24. Poulikakos P.I., Solit D.B. Resistance to MEK inhibitors: should we co-target upstream?. Sci. Signal. 2011, 4:pe16.
25. Robinson R.A., Lu X., Jones E.Y., Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 2008, 16:259-268.
26. Rudolf E., Rudolf K., Cervinka M. Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 2011, 16:1165-1176.
27. Sachdev S., Hoffmann A., Hannink M. Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences. Mol. Cell. Biol. 1998, 18:2524-2534.
28. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 2001, 8:781-794.
29. Slee E.A., Gillotin S., Bergamaschi D., Royer C., Llanos S., Ali S., Jin B., Trigiante G., Lu X. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 2004, 23:9007-9016.
30. Slee E.A., Benassi B., Goldin R., Zhong S., Ratnayaka I., Blandino G., Lu X. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proc. Natl. Acad. Sci. USA 2010, 107:19479-19484.
31. Song Y., Zhao C., Dong L., Fu M., Xue L., Huang Z., Tong T., Zhou Z., Chen A., Yang Z., et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis 2008, 29:307-315.
32. Terzian T., Torchia E.C., Dai D., Robinson S.E., Murao K., Stiegmann R.A., Gonzalez V., Boyle G.M., Powell M.B., Pollock P.M., et al. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010, 23:781-794.
33. Tseng H.Y., Jiang C.C., Croft A., Tay K.H., Thorne R.F., Yang F., Liu H., Hersey P., Zhang X.D. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Ther. 2010, 9:3363-3374.
34. Van Impe K., Hubert T., De Corte V., Vanloo B., Boucherie C., Vandekerckhove J., Gettemans J. A new role for nuclear transport factor 2 and Ran: nuclear import of CapG. Traffic 2008, 9:695-707.
35. Vu B.T., Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 2011, 348:151-172.
36. Wang Y., Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 1995, 376:88-91.
37. Yang J.P., Hori M., Sanda T., Okamoto T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J. Biol. Chem. 1999, 274:15662-15670.
38. Yang G., Rajadurai A., Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J. Invest. Dermatol. 2005, 125:1242-1251.
39. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.